Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Nuvalent, Inc. Market Cap
From what 13 stock analysts predict, the share price for Nuvalent, Inc. (NUVL) might increase by 24.25% in the next year. This is based on a 12-month average estimation for NUVL. Price targets go from $100 to $137. The majority of stock analysts believe NUVL is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 13 Wall Street analysts have assignedNUVL 12 buy ratings, 1 hold ratings, and 0 sell ratings. This means that analysts expect Nuvalent, Inc. to buy. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on NUVL. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of NUVL.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Etzer Darout BMO Capital | Outperform | $134 | Maintains | Nov 13, 2024 |
| David Dai UBS | Neutral | $100 | Initiates | Oct 24, 2024 |
| Anupam Rama JP Morgan | Overweight | $125 | Maintains | Oct 4, 2024 |
| David Nierengarten Wedbush | Outperform | $115 | Maintains | Sep 16, 2024 |
| Etzer Darout BMO Capital | Outperform | $132 | Maintains | Sep 16, 2024 |
| Kelsey Goodwin Guggenheim | Buy | $105 | Maintains | Sep 16, 2024 |
| Bradley Canino Stifel | Buy | $135 | Maintains | Sep 16, 2024 |
| David Nierengarten Wedbush | Outperform | $99 | Reiterates | Sep 9, 2024 |
| Anupam Rama JP Morgan | Overweight | $100 | Maintains | Sep 4, 2024 |
| Carter Gould Barclays | Overweight | $100 | Initiates | Aug 29, 2024 |
| Bradley Canino Stifel | Buy | $115 | Maintains | Jul 10, 2024 |
| David Nierengarten Wedbush | Outperform | $99 | Reiterates | May 17, 2024 |
| Roger Song Jefferies | Buy | $97 | Initiates | Apr 17, 2024 |
| Andrew Berens Leerink Partners | Outperform | $110 | Upgrade | Apr 1, 2024 |
| Anupam Rama JP Morgan | Overweight | $98 | Maintains | Mar 6, 2024 |
| Etzer Darout BMO Capital | Outperform | $102 | Maintains | Feb 28, 2024 |
| Kelsey Goodwin Guggenheim | Buy | $99 | Assumes | Feb 28, 2024 |
| Colleen Kusy Baird | Outperform | $105 | Initiates | Feb 23, 2024 |
| Etzer Darout BMO Capital | Outperform | $79 | Maintains | Oct 19, 2023 |
| Anupam Rama JP Morgan | Overweight | $68 | Maintains | Oct 5, 2023 |
When did it IPO
2021
Staff Count
127
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. James R. Porter Ph.D.
Market Cap
$6.88B
In 2023, NUVL generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that NUVL's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 09 Dec 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Nuvalent, Inc. (Nasdaq: NUVL) appointed Grant Bogle to its Board of Directors, enhancing its leadership as it develops targeted cancer therapies.
Why It Matters - Grant Bogle's appointment to Nuvalent's Board may enhance strategic direction and credibility, potentially influencing investor confidence and stock performance in the biotech sector.
Tue, 26 Nov 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Nuvalent, Inc. (Nasdaq: NUVL) will participate in a fireside chat at the Piper Sandler Healthcare Conference on December 3, 2024, featuring CEO James Porter and CFO Alexandra Balcom.
Why It Matters - Nuvalent's participation in a prominent healthcare conference highlights its visibility and potential investor interest, signaling advancements in its targeted cancer therapies.
Tue, 12 Nov 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Company on track for 2024 milestones under OnTarget 2026 plan, with cash reserves of $1.2 billion post $575 million offering. Alice Shaw joins Scientific Advisory Board.
Why It Matters - The achievement of milestones and robust cash position suggest strong growth potential and operational stability, positively influencing investor confidence in the company's future.
Mon, 23 Sep 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - Nuvalent's NVL-520 and NVL-655 show promising results in trials, have FDA designations, and pivotal data is expected in 2025. A $500M offering secures funding through Phase 3.
Why It Matters - Nuvalent's promising drug trials and FDA designations enhance growth potential, while the $500 million offering signals strong investor confidence and financial stability for further development.
Wed, 18 Sep 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Nuvalent, Inc. closed its upsized public offering of 5.75 million shares of Class A common stock at $100.00 per share, including an additional 750,000 shares from underwriters' options.
Why It Matters - Nuvalent's upsized public offering raises significant capital, enhancing its financial stability and funding for targeted cancer therapies, which could drive future growth and stock performance.
Wed, 18 Sep 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - NUVL reported positive data on two experimental lung cancer therapies, leading to an increase in investor interest.
Why It Matters - Positive data on NUVL's lung cancer therapies could indicate strong future revenue potential, impacting stock performance and investor sentiment in the biotech sector.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
